Please assess the completion status of the following clinical trial:

Trial Title: Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.~* Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.~* Use of one (1), but no more than two (2) concomitant marketed antiepileptic drugs (AEDs) at the time of trial entry.~Exclusion Criteria:~* Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.~* Presence of known pseudoseizures within the last year.~* Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.~* Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): Subjects received open-label Levetiracetam.

Based on this trial design, predict the completion outcome and termination type (if applicable).